Search

We examined the role of family support in influencing attitudes about social distancing and positive mental health during the COVID-19 pandemic among 1547 Chinese people. The results showed that after the effects of demographic variables were controlled, perceived support from family members made unique contributions to their attitudes about social distancing and positive mental health both directly and indirectly (via buffering loneliness). These results suggest that strong support from family plays an important role in improving individuals’ attitudes about social distancing and maintaining positive mental health during the epidemic. [ABSTRACT FROM AUTHOR]

A recent study showed that a brief intervention involving reflection on personal values (T1: 2 February 2020) can buffer the anxiety response one week later (T2: Feb. 9) during the COVID-19 pandemic in China. The present study reported the results from a follow-up two weeks (T3: Feb. 16) and one-month later (T4: Mar. 1). Two hundred and twenty participants were recruited via convenience sampling and randomly assigned either to the value-affirmation condition or to a control condition, with 110 participants in each condition. The results revealed that similar to T2, participants who affirmed their values showed a lower anxiety response than those in the control group at T3, despite the pandemic continuing to increase rapidly during that time. Meanwhile, anxiety decreased in both groups at T4 as the pandemic eased. Findings suggest that self-affirmations can help reduce stress in the face of the COVID-19. [ABSTRACT FROM AUTHOR]

Patients with major psychiatric disorders (MPD) that include schizophrenia (SCH), bipolar disorder (BP), and major depressive disorder (MDD) are at increased risk for coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccines in MPD patients have not been fully evaluated. This study aimed to investigate adverse events (AEs)/side effects and efficacy of COVID-19 vaccines in MPD patients. This retrospective study included 2034 patients with SCH, BP, or MDD who voluntarily received either BBIBP-CorV or Sinovac COVID-19 vaccines, and 2034 matched healthy controls. The incidence of AEs/side effects and the efficacy of COIVD-19 vaccinations among the two groups were compared. The risk ratio (RR) of side effects in patients with MPD was 0.60 (95% confidence interval [CI]: 0.53-0.68) after the first dose and 0.80 (95% CI: 0.65-0.99) following the second dose, suggesting a significantly lower risk in the MPD group versus healthy controls. The RRs of AEs did not differ between patients and controls. Notably, fully vaccinated patients exhibited a decreased risk of influenza with or without fever compared with controls (RR=0.38, 95% CI: 0.31-0.46; RR=0.23, 95% CI: 0.17-0.30; respectively). Further subgroup comparisons revealed a significantly lower risk of influenza with fever in MDD (RR=0.13, 95% CI: 0.08-0.21) and SCH (RR=0.24, 95% CI: 0.17-0.34) than BP (RR=0.85, 95% CI: 0.69-1.06) compared to controls. We conclude that the benefit-risk ratio of COVID-19 vaccination was more favorable in SCH or MDD versus BP when compared with controls. These data indicate that COVID-19 vaccines are safe and protective in patients with MPD from COVID-19., Competing Interests: None., (AJTR Copyright © 2022.)